ImmunityBio, Inc.

XNASHealth care

Last traded price · USD

$8.89

−0.45%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.93
Volume: 5,153
Day's high: —
Day's low: —

In brief

ImmunityBio, Inc. is a health care company listed on Nasdaq, valued at about $9.42B.
Its shares closed at $8.93 on 4 Nov 2026, up 329.3% over the past year.
From India you can buy IBRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ImmunityBio, Inc. (IBRX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IBRX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IBRX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −7.8% (SPY −1.6%, XLV +13.5%). 3 months: +23.2% (SPY −0.4%, XLV +15.5%). 1 year: +329.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IBRX, SPY and XLV · as of 4 Nov 2026
7.2 days to cover short interest
122.9M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 1.06B shares outstanding; covering them would take 7.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $8.93 was 2.2% above its 50-day average ($8.74) and 12.4% above its 200-day average ($7.95). It has closed above the 200-day for 206 sessions, since 12 Jan 2026. The 50-day average crossed above the 200-day on 23 Jan 2026, 197 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
67% of the way up its 52-week range
Closed at $8.93 on 4 Nov 2026: 28.2% below the 52-week high of $12.43 (25 Feb 2026) and 357.9% above the low of $1.95 (31 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−7.8%

6 months+6.6%

1 year+329.3%

5 years+3.5%

Newswire

About

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Website

Notable moves

April 26, 2024
+43.84%
May 11, 2023
−55.14%
May 5, 2023
+43.15%

Newswire

About

Website

Notable moves

April 26, 2024
+43.84%
May 11, 2023
−55.14%
May 5, 2023
+43.15%

ImmunityBio, Inc.

XNASHealth care

Last traded price · USD

$8.89

−0.45%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $8.93
Volume: 5,153
Day's high: —
Day's low: —

In brief

ImmunityBio, Inc. is a health care company listed on Nasdaq, valued at about $9.42B.
Its shares closed at $8.93 on 4 Nov 2026, up 329.3% over the past year.
From India you can buy IBRX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy ImmunityBio, Inc. (IBRX) shares from India?

Do I need the price of a whole IBRX share to invest?

How much can I invest in US stocks in a year?

Can I trade IBRX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −7.8% (SPY −1.6%, XLV +13.5%). 3 months: +23.2% (SPY −0.4%, XLV +15.5%). 1 year: +329.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IBRX, SPY and XLV · as of 4 Nov 2026
7.2 days to cover short interest
122.9M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 1.06B shares outstanding; covering them would take 7.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $8.93 was 2.2% above its 50-day average ($8.74) and 12.4% above its 200-day average ($7.95). It has closed above the 200-day for 206 sessions, since 12 Jan 2026. The 50-day average crossed above the 200-day on 23 Jan 2026, 197 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
67% of the way up its 52-week range
Closed at $8.93 on 4 Nov 2026: 28.2% below the 52-week high of $12.43 (25 Feb 2026) and 357.9% above the low of $1.95 (31 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−7.8%

6 months+6.6%

1 year+329.3%

5 years+3.5%

Newswire

About

Website

Notable moves

April 26, 2024
+43.84%
May 11, 2023
−55.14%
May 5, 2023
+43.15%

Newswire

About

Website

Notable moves

April 26, 2024
+43.84%
May 11, 2023
−55.14%
May 5, 2023
+43.15%

ImmunityBio, Inc.

ImmunityBio, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.2 days to cover short interest

Above its 50- and 200-day averages

67% of the way up its 52-week range

ImmunityBio, Inc.

ImmunityBio, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.2 days to cover short interest

Above its 50- and 200-day averages

67% of the way up its 52-week range